Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mi-Heon Lee"'
Autor:
Kachroo, Puja1,2,3 puja.kachroo@gmail.com, Mi-Heon Lee1,3 mi-heonlee@mednet.ucla.edu, Ling Zhang1,3 lizhang@llu.edu, Baratelli, Felicita1,2 felicita.baratelli@gmail.com, Gina Lee1,2 leex0455@umn.edu, Srivastava, Minu K.1,4 msrivastava@mednet.ucla.edu, Wang, Gerald1,2 geraldwang@mednet.ucla.edu, Walser, Tonya C.1,2 twalser@mednet.ucla.edu, Krysan, Kostyantyn1,2 kkrysan@mednet.ucla.edu, Sharma, Sherven1,4 ssharma@mednet.ucla.edu, Dubinett, Steven M.1,2,4 sdubinett@mednet.ucla.edu, Lee, Jay M.1,2,3,5 jaymoonlee@mednet.ucla.edu
Publikováno v:
Journal of Experimental & Clinical Cancer Research (17569966). 2013, Vol. 32 Issue 1, p1-28. 28p.
Autor:
Sherven Sharma, Paul Pagano, Kostyantyn Krysan, Steven M. Dubinett, Gerald Wang, Mi-Heon Lee, Jane Yanagawa, Jay M. Lee, Maie A. St. John, Tonya C. Walser, Puja Kachroo
Publikováno v:
Lee, M-H; Kachroo, P; Pagano, PC; Yanagawa, J; Wang, G; Walser, TC; et al.(2014). Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway.. Journal of cancer science & therapy, 6(11), 468-477. doi: 10.4172/1948-5956.1000310. UCLA: Retrieved from: http://www.escholarship.org/uc/item/4q6540ds
Journal of cancer science & therapy, vol 6, iss 11
Journal of cancer science & therapy, vol 6, iss 11
BackgroundThe cyclooxygenase 2 (COX-2) pathway has been implicated in the molecular pathogenesis of many malignancies, including lung cancer. Apricoxib, a selective COX-2 inhibitor, has been described to inhibit epithelial-mesenchymal transition (EMT
Autor:
Gerald Wang, Mi Heon Lee, Felicita Baratelli, Ling Zhang, Steven M. Dubinett, Sherven Sharma, Tonya C. Walser, Puja Kachroo, Gina Lee, Jay M. Lee, Minu K. Srivastava, Kostyantyn Krysan
Publikováno v:
Kachroo, Puja; Lee, Mi-Heon; Zhang, Ling; Baratelli, Felicita; Lee, Gina; Srivastava, Minu K; et al.(2013). IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. Journal of Experimental & Clinical Cancer Research, 32(1), 97. doi: http://dx.doi.org/10.1186/1756-9966-32-97. Retrieved from: http://www.escholarship.org/uc/item/2zr912pg
Journal of Experimental & Clinical Cancer Research : CR
Kachroo, P; Lee, MH; Zhang, L; Baratelli, F; Lee, G; Srivastava, MK; et al.(2013). IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 32(1). doi: 10.1186/1756-9966-32-97. UCLA: Retrieved from: http://www.escholarship.org/uc/item/38f8k949
Journal of Experimental & Clinical Cancer Research : CR
Kachroo, P; Lee, MH; Zhang, L; Baratelli, F; Lee, G; Srivastava, MK; et al.(2013). IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 32(1). doi: 10.1186/1756-9966-32-97. UCLA: Retrieved from: http://www.escholarship.org/uc/item/38f8k949
Background Interleukin-27 signaling is mediated by the JAK-STAT pathway via activation of STAT1 and STAT3, which have tumor suppressive and oncogenic activities, respectively. Epithelial–mesenchymal transition (EMT) and angiogenesis are key process